<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114893</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-075</org_study_id>
    <nct_id>NCT01114893</nct_id>
  </id_info>
  <brief_title>Travoprost Five Day Posology Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of three concentrations of
      travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5</measure>
    <time_frame>5 days</time_frame>
    <description>Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP Change From Baseline at 8 PM on Day 5</measure>
    <time_frame>5 Days</time_frame>
    <description>Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Open-angle Glaucoma (OAG)</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TRAVATAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TRAVATAN 0.004% once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Travoprost Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Group C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004%</intervention_name>
    <description>1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days</description>
    <arm_group_label>TRAVATAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Vehicle</intervention_name>
    <description>1 drop in each eye 8 times daily for 5 days</description>
    <arm_group_label>Travoprost Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost (Groups A, B and C)</intervention_name>
    <description>1 drop in each eye 8 times daily for 5 days</description>
    <arm_group_label>Travoprost Group A</arm_group_label>
    <arm_group_label>Travoprost Group B</arm_group_label>
    <arm_group_label>Travoprost Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. either sex and any race/ethnicity, ≥18 years old

          2. diagnosed with open-angle glaucoma, and/or ocular hypertension

          3. meets the following IOP entry criteria:

               -  Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye
                  qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1

               -  Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day
                  0), and at 8 AM on Day 1

          4. satisfies all informed consent requirements; able to read, sign and date the informed
             consent

        Exclusion Criteria:

          1. females of childbearing potential not meeting protocol conditions

          2. angle grade less than Grade 2 in either eye

          3. cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye

          4. severe central visual field loss in either eye

          5. any abnormality preventing reliable applanation tonometry in either eye

          6. hypersensitivity to prostaglandin analogues or to any component of the study
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <results_first_submitted>May 26, 2011</results_first_submitted>
  <results_first_submitted_qc>May 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2011</results_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Matt Walker, PhD</name_title>
    <organization>Alcon Research, Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TRAVATAN</title>
          <description>TRAVATAN 0.004% once daily</description>
        </group>
        <group group_id="P2">
          <title>Travoprost Vehicle</title>
          <description>Travoprost Vehicle</description>
        </group>
        <group group_id="P3">
          <title>Travoprost Group A</title>
          <description>Travoprost Group A</description>
        </group>
        <group group_id="P4">
          <title>Travoprost Group B</title>
          <description>Travoprost Group B</description>
        </group>
        <group group_id="P5">
          <title>Travoprost Group C</title>
          <description>Travoprost Group C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TRAVATAN</title>
          <description>TRAVATAN 0.004% once daily</description>
        </group>
        <group group_id="B2">
          <title>Travoprost Vehicle</title>
          <description>Travoprost Vehicle</description>
        </group>
        <group group_id="B3">
          <title>Travoprost Group A</title>
          <description>Travoprost Group A</description>
        </group>
        <group group_id="B4">
          <title>Travoprost Group B</title>
          <description>Travoprost Group B</description>
        </group>
        <group group_id="B5">
          <title>Travoprost Group C</title>
          <description>Travoprost Group C</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5</title>
        <description>Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Travatan 0.004% QD</title>
          </group>
          <group group_id="O2">
            <title>Travoprost Vehicle</title>
          </group>
          <group group_id="O3">
            <title>Travoprost Group A</title>
          </group>
          <group group_id="O4">
            <title>Travoprost Group B</title>
          </group>
          <group group_id="O5">
            <title>Travoprost Group C</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5</title>
          <description>Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" lower_limit="-12.5" upper_limit="-7.0"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-4.7" upper_limit="-1.0"/>
                    <measurement group_id="O3" value="-5.0" lower_limit="-6.7" upper_limit="-3.3"/>
                    <measurement group_id="O4" value="-6.5" lower_limit="-8.7" upper_limit="-4.4"/>
                    <measurement group_id="O5" value="-6.8" lower_limit="-8.5" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IOP Change From Baseline at 8 PM on Day 5</title>
        <description>Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment</description>
        <time_frame>5 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Travatan 0.004% QD</title>
          </group>
          <group group_id="O2">
            <title>Travoprost Vehicle</title>
          </group>
          <group group_id="O3">
            <title>Travoprost Group A</title>
          </group>
          <group group_id="O4">
            <title>Travoprost Group B</title>
          </group>
          <group group_id="O5">
            <title>Travoprost Group C</title>
          </group>
        </group_list>
        <measure>
          <title>IOP Change From Baseline at 8 PM on Day 5</title>
          <description>Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-6.2" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.6" upper_limit="0.7"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-4.3" upper_limit="-1.2"/>
                    <measurement group_id="O4" value="-5.7" lower_limit="-7.5" upper_limit="-3.9"/>
                    <measurement group_id="O5" value="-4.8" lower_limit="-6.1" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TRAVATAN</title>
          <description>TRAVATAN 0.004% once daily</description>
        </group>
        <group group_id="E2">
          <title>Travoprost Vehicle</title>
          <description>Travoprost Vehicle</description>
        </group>
        <group group_id="E3">
          <title>Travoprost Group A</title>
          <description>Travoprost Group A</description>
        </group>
        <group group_id="E4">
          <title>Travoprost Group B</title>
          <description>Travoprost Group B</description>
        </group>
        <group group_id="E5">
          <title>Travoprost Group C</title>
          <description>Travoprost Group C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (version 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Corneal Staining</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Lt.d</organization>
      <phone>888.451.3937 ext 817.568.67</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

